The Company
is advised by a number of highly experienced scientific and business
consultants.
Michael Andreeff, M.D., Ph.D.
Dr. Michael Andreeff received his M.D. and Ph.D.
degrees from the University of Heidelberg in Germany and additional training
and faculty appointments at Memorial Sloan-Kettering Cancer Center in the
Departments of Pathology and Leukemia. He
has been a pioneer in flow cytometry since 1971, when he established the first
flow cytometry laboratory at the University of Heidelberg and organized the
first European conference on flow cytometry. In 1977, he joined Memorial
Sloan-Kettering Cancer Center as head of the Leukemia Cell Biology and
Hematopathology flow cytometry laboratory. He is currently a professor of
medicine and holds the Paul and Mary Haas Chair in Genetics at MD Anderson. He
has authored more than 450 published peer-reviewed papers, 5 books, and 75 book
chapters.
He and his group have worked extensively on drug resistance in
hematopoietic malignancies and breast cancer and developed or co-developed
several new therapeutic agents, including the novel triterpenoids CDDO and CDDO-Me
and Bcl-2, XIAP, survivin, MEK, and HDM2 inhibitors. He has published a number
of papers on the utility of triptolide in models of AML.
Adil Daud, M.D.
Dr. Adil Daud, Director of Melanoma
Clinical Research and Director of the Melanoma Program at the University of California, San Francisco (UCSF), is a specialist in melanoma and other skin cancers. In addition to
caring for patients, he directs melanoma research to better understand the
biology of melanoma and to develop new treatments for the disease. He has
developed and led numerous early phase and melanoma specific clinical trials that have expanded the use of gene
therapy for melanoma.
Dr. Daud earned a medical degree at the Government Medical College
in Nagpur, India. He completed an internship and residency in internal medicine
at Indiana University Medical Center, followed by a fellowship in
hematology-oncology at Memorial Sloan-Kettering Cancer Center. Prior to joining
UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa,
Fla. for seven years. Dr. Daud has won numerous awards, including the American
Society for Clinical Oncology's Young Investigator award and Castle Connolly's
Best Doctors in America award. He is an HS Clinical Professor of Medicine at UCSF.
Ann Welton, Ph.D.
Dr. Welton
was a senior level pharmaceutical company executive leader in drug discovery
research and early development for over 30 years before retiring in 2010. She
has worked in multidisciplinary R&D environments in both large
multinational pharmaceutical and biotechnology companies. From 1977 to 1997 she
held leadership positions at Hoffmann LaRoche in Nutley, N.J. in Inflammation
and Respiratory drug discovery research which culminated in her roles as
Vice-President of Bronchopulmonary Research (1992-1994) and Vice-President of
Nonclinical Development (1994-1997).
From 1998 to 2003, Dr. Welton was Vice-President of Biology and
Preclinical Development at the biotechnology company, Axys Pharmaceuticals
(which in 2002 was acquired by Celera).
From 2003 to 2010 Dr. Welton was Compound Development Team Leader for
Immunology early development projects at the Johnson & Johnson Research
Center in La Jolla, CA. Dr. Welton
received her Ph.D. in Biochemistry from Michigan State University and was a
post-doctoral fellow at NIH in the Laboratory of the Nobel Laureate, Dr. Martin
Rodbell, prior to joining the pharmaceutical industry.
Margaret (Peg) A. Horn, J.D.
Ms. Horn
has over 25 years of experience in the pharmaceutical and biotechnology
industries with an emphasis on transactions (including licensing, product
acquisitions and divestitures, M&A) and intellectual property related
matters. Most recently she is the
founder of Transact Business Consulting LLC and Chief Operating Officer of
ProLynx LLC. Prior to founding Transact she was SVP, Corporate Development and
General Counsel at Cogentus Pharmaceuticals and at Kosan Biosciences, Inc
(KOSN). Ms. Horn began her biotech career
at Genencor International (GCOR) where she served in several capacities between
1991 and 2005, initially as patent counsel and finally as Senior Vice President
of Legal and General Counsel. She began her career counseling the
pharmaceutical division of E.I. du Pont de Nemours & Company.